What's Happening?
Delcath Systems, Inc. has initiated a Phase 2 clinical trial for its HEPZATO treatment in patients with liver-dominant metastatic breast cancer. The trial, conducted at the European Institute of Oncology in Milan, Italy, will assess the safety and efficacy
of HEPZATO combined with standard care treatments. Approximately 90 patients will participate in this randomized trial across multiple sites in the U.S. and Europe. The primary endpoint is hepatic progression-free survival, with secondary endpoints including overall survival and response rates.
Why It's Important?
This trial represents a significant advancement in addressing the unmet needs of patients with liver-dominant metastatic breast cancer, a group with limited treatment options. HEPZATO's potential to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure could offer a new therapeutic avenue for these patients. Success in this trial could lead to broader adoption of liver-directed therapies in oncology, potentially improving survival rates and quality of life for affected patients.
What's Next?
As the trial progresses, Delcath will focus on enrolling patients and gathering data to evaluate HEPZATO's effectiveness. Positive results could pave the way for regulatory approvals and expanded use of the treatment in other cancer types. The company will also continue to engage with healthcare providers to educate them on the benefits of liver-directed therapies, potentially influencing future treatment protocols in oncology.
